| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/2162402X.2015.1071009 |
| P8608 | Fatcat ID | release_i3k3oakv3rhnjfkljmyy4dy5hy |
| P932 | PMC publication ID | 4801466 |
| P698 | PubMed publication ID | 27057437 |
| P2093 | author name string | Dominik Wolf | |
| Janna Rudolph | |||
| Kathrin Schönberg | |||
| Sowmya Parampalli Yajnanarayana | |||
| P2860 | cites work | A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 |
| Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells | Q34298729 | ||
| The V617F JAK2 mutation and the myeloproliferative disorders | Q36312018 | ||
| JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation? | Q38009904 | ||
| JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms | Q41127061 | ||
| JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms | Q41138516 | ||
| The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo | Q43451422 | ||
| Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? | Q54393708 | ||
| Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 | ||
| P433 | issue | 2 | |
| P304 | page(s) | e1071009 | |
| P577 | publication date | 2015-08-12 | |
| P1433 | published in | OncoImmunology | Q18026500 |
| P1476 | title | Get a grip on immune cells by inhibiting JAKs | |
| P478 | volume | 5 |
Search more.